世界の低悪性度リンパ腫治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Indolent Lymphoma Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3087 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、低悪性度リンパ腫治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（BI-836826、ALT-803、BMS-986016、CC-122、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・低悪性度リンパ腫治療の市場動向 ・企業の競争状況、市場シェア ・低悪性度リンパ腫治療の種類別市場規模（BI-836826、ALT-803、BMS-986016、CC-122、その他） ・低悪性度リンパ腫治療の用途別市場規模（病院、クリニック、その他） ・低悪性度リンパ腫治療の北米市場規模2016-2027（アメリカ、カナダ） ・低悪性度リンパ腫治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・低悪性度リンパ腫治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・低悪性度リンパ腫治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・低悪性度リンパ腫治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Altor BioScience Corporation、Amgen Inc.、Astellas Pharma Inc.、Bayer AG、Boehringer Ingelheim GmbH、Bristol-Myers Squibb Company、Celgene Corporation、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.、Gilead Sciences, Inc.、Incyte Corporation、Infinity Pharmaceuticals, Inc.、Juno Therapeutics Inc.、MedImmune, LLC） ・結論

Market Analysis and Insights: Global Indolent Lymphoma Treatment Market
The global Indolent Lymphoma Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Indolent Lymphoma Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Indolent Lymphoma Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Indolent Lymphoma Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Indolent Lymphoma Treatment market.

Global Indolent Lymphoma Treatment Scope and Market Size
Indolent Lymphoma Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Indolent Lymphoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
BI-836826
ALT-803
BMS-986016
CC-122
Others

Segment by Application
Hospital
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Bayer AG
Boehringer Ingelheim GmbH
Infinity Pharmaceuticals, Inc.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Indolent Lymphoma Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 BI-836826
1.2.3 ALT-803
1.2.4 BMS-986016
1.2.5 CC-122
1.2.6 Others
1.3 Market by Application
1.3.1 Global Indolent Lymphoma Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Indolent Lymphoma Treatment Market Perspective (2016-2027)
2.2 Indolent Lymphoma Treatment Growth Trends by Regions
2.2.1 Indolent Lymphoma Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Indolent Lymphoma Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Indolent Lymphoma Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Indolent Lymphoma Treatment Industry Dynamic
2.3.1 Indolent Lymphoma Treatment Market Trends
2.3.2 Indolent Lymphoma Treatment Market Drivers
2.3.3 Indolent Lymphoma Treatment Market Challenges
2.3.4 Indolent Lymphoma Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Indolent Lymphoma Treatment Players by Revenue
3.1.1 Global Top Indolent Lymphoma Treatment Players by Revenue (2016-2021)
3.1.2 Global Indolent Lymphoma Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Indolent Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Indolent Lymphoma Treatment Revenue
3.4 Global Indolent Lymphoma Treatment Market Concentration Ratio
3.4.1 Global Indolent Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Indolent Lymphoma Treatment Revenue in 2020
3.5 Indolent Lymphoma Treatment Key Players Head office and Area Served
3.6 Key Players Indolent Lymphoma Treatment Product Solution and Service
3.7 Date of Enter into Indolent Lymphoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Indolent Lymphoma Treatment Breakdown Data by Type
4.1 Global Indolent Lymphoma Treatment Historic Market Size by Type (2016-2021)
4.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Type (2022-2027)

5 Indolent Lymphoma Treatment Breakdown Data by Application
5.1 Global Indolent Lymphoma Treatment Historic Market Size by Application (2016-2021)
5.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Indolent Lymphoma Treatment Market Size (2016-2027)
6.2 North America Indolent Lymphoma Treatment Market Size by Type
6.2.1 North America Indolent Lymphoma Treatment Market Size by Type (2016-2021)
6.2.2 North America Indolent Lymphoma Treatment Market Size by Type (2022-2027)
6.2.3 North America Indolent Lymphoma Treatment Market Size by Type (2016-2027)
6.3 North America Indolent Lymphoma Treatment Market Size by Application
6.3.1 North America Indolent Lymphoma Treatment Market Size by Application (2016-2021)
6.3.2 North America Indolent Lymphoma Treatment Market Size by Application (2022-2027)
6.3.3 North America Indolent Lymphoma Treatment Market Size by Application (2016-2027)
6.4 North America Indolent Lymphoma Treatment Market Size by Country
6.4.1 North America Indolent Lymphoma Treatment Market Size by Country (2016-2021)
6.4.2 North America Indolent Lymphoma Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Indolent Lymphoma Treatment Market Size (2016-2027)
7.2 Europe Indolent Lymphoma Treatment Market Size by Type
7.2.1 Europe Indolent Lymphoma Treatment Market Size by Type (2016-2021)
7.2.2 Europe Indolent Lymphoma Treatment Market Size by Type (2022-2027)
7.2.3 Europe Indolent Lymphoma Treatment Market Size by Type (2016-2027)
7.3 Europe Indolent Lymphoma Treatment Market Size by Application
7.3.1 Europe Indolent Lymphoma Treatment Market Size by Application (2016-2021)
7.3.2 Europe Indolent Lymphoma Treatment Market Size by Application (2022-2027)
7.3.3 Europe Indolent Lymphoma Treatment Market Size by Application (2016-2027)
7.4 Europe Indolent Lymphoma Treatment Market Size by Country
7.4.1 Europe Indolent Lymphoma Treatment Market Size by Country (2016-2021)
7.4.2 Europe Indolent Lymphoma Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Indolent Lymphoma Treatment Market Size (2016-2027)
8.2 Asia-Pacific Indolent Lymphoma Treatment Market Size by Type
8.2.1 Asia-Pacific Indolent Lymphoma Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Indolent Lymphoma Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Indolent Lymphoma Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Indolent Lymphoma Treatment Market Size by Application
8.3.1 Asia-Pacific Indolent Lymphoma Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Indolent Lymphoma Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Indolent Lymphoma Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Indolent Lymphoma Treatment Market Size by Region
8.4.1 Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Indolent Lymphoma Treatment Market Size (2016-2027)
9.2 Latin America Indolent Lymphoma Treatment Market Size by Type
9.2.1 Latin America Indolent Lymphoma Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Indolent Lymphoma Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Indolent Lymphoma Treatment Market Size by Type (2016-2027)
9.3 Latin America Indolent Lymphoma Treatment Market Size by Application
9.3.1 Latin America Indolent Lymphoma Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Indolent Lymphoma Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Indolent Lymphoma Treatment Market Size by Application (2016-2027)
9.4 Latin America Indolent Lymphoma Treatment Market Size by Country
9.4.1 Latin America Indolent Lymphoma Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Indolent Lymphoma Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Indolent Lymphoma Treatment Market Size (2016-2027)
10.2 Middle East & Africa Indolent Lymphoma Treatment Market Size by Type
10.2.1 Middle East & Africa Indolent Lymphoma Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Indolent Lymphoma Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Indolent Lymphoma Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Indolent Lymphoma Treatment Market Size by Application
10.3.1 Middle East & Africa Indolent Lymphoma Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Indolent Lymphoma Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Indolent Lymphoma Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Indolent Lymphoma Treatment Market Size by Country
10.4.1 Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Altor BioScience Corporation
11.1.1 Altor BioScience Corporation Company Details
11.1.2 Altor BioScience Corporation Business Overview
11.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Introduction
11.1.4 Altor BioScience Corporation Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.1.5 Altor BioScience Corporation Recent Development
11.2 Amgen Inc.
11.2.1 Amgen Inc. Company Details
11.2.2 Amgen Inc. Business Overview
11.2.3 Amgen Inc. Indolent Lymphoma Treatment Introduction
11.2.4 Amgen Inc. Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.2.5 Amgen Inc. Recent Development
11.3 Astellas Pharma Inc.
11.3.1 Astellas Pharma Inc. Company Details
11.3.2 Astellas Pharma Inc. Business Overview
11.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Introduction
11.3.4 Astellas Pharma Inc. Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.3.5 Astellas Pharma Inc. Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Details
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Indolent Lymphoma Treatment Introduction
11.4.4 Bayer AG Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.4.5 Bayer AG Recent Development
11.5 Boehringer Ingelheim GmbH
11.5.1 Boehringer Ingelheim GmbH Company Details
11.5.2 Boehringer Ingelheim GmbH Business Overview
11.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Introduction
11.5.4 Boehringer Ingelheim GmbH Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.5.5 Boehringer Ingelheim GmbH Recent Development
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Details
11.6.2 Bristol-Myers Squibb Company Business Overview
11.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Introduction
11.6.4 Bristol-Myers Squibb Company Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.6.5 Bristol-Myers Squibb Company Recent Development
11.7 Celgene Corporation
11.7.1 Celgene Corporation Company Details
11.7.2 Celgene Corporation Business Overview
11.7.3 Celgene Corporation Indolent Lymphoma Treatment Introduction
11.7.4 Celgene Corporation Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.7.5 Celgene Corporation Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Introduction
11.8.4 Eli Lilly and Company Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.8.5 Eli Lilly and Company Recent Development
11.9 F. Hoffmann-La Roche Ltd.
11.9.1 F. Hoffmann-La Roche Ltd. Company Details
11.9.2 F. Hoffmann-La Roche Ltd. Business Overview
11.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Introduction
11.9.4 F. Hoffmann-La Roche Ltd. Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.9.5 F. Hoffmann-La Roche Ltd. Recent Development
11.10 Gilead Sciences, Inc.
11.10.1 Gilead Sciences, Inc. Company Details
11.10.2 Gilead Sciences, Inc. Business Overview
11.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Introduction
11.10.4 Gilead Sciences, Inc. Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.10.5 Gilead Sciences, Inc. Recent Development
11.11 Incyte Corporation
11.11.1 Incyte Corporation Company Details
11.11.2 Incyte Corporation Business Overview
11.11.3 Incyte Corporation Indolent Lymphoma Treatment Introduction
11.11.4 Incyte Corporation Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.11.5 Incyte Corporation Recent Development
11.12 Infinity Pharmaceuticals, Inc.
11.12.1 Infinity Pharmaceuticals, Inc. Company Details
11.12.2 Infinity Pharmaceuticals, Inc. Business Overview
11.12.3 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Introduction
11.12.4 Infinity Pharmaceuticals, Inc. Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.12.5 Infinity Pharmaceuticals, Inc. Recent Development
11.13 Juno Therapeutics Inc.
11.13.1 Juno Therapeutics Inc. Company Details
11.13.2 Juno Therapeutics Inc. Business Overview
11.13.3 Juno Therapeutics Inc. Indolent Lymphoma Treatment Introduction
11.13.4 Juno Therapeutics Inc. Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.13.5 Juno Therapeutics Inc. Recent Development
11.14 MedImmune, LLC
11.14.1 MedImmune, LLC Company Details
11.14.2 MedImmune, LLC Business Overview
11.14.3 MedImmune, LLC Indolent Lymphoma Treatment Introduction
11.14.4 MedImmune, LLC Revenue in Indolent Lymphoma Treatment Business (2016-2021)
11.14.5 MedImmune, LLC Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Indolent Lymphoma Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of BI-836826
Table 3. Key Players of ALT-803
Table 4. Key Players of BMS-986016
Table 5. Key Players of CC-122
Table 6. Key Players of Others
Table 7. Global Indolent Lymphoma Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Indolent Lymphoma Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Indolent Lymphoma Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Indolent Lymphoma Treatment Market Share by Regions (2016-2021)
Table 11. Global Indolent Lymphoma Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Indolent Lymphoma Treatment Market Share by Regions (2022-2027)
Table 13. Indolent Lymphoma Treatment Market Trends
Table 14. Indolent Lymphoma Treatment Market Drivers
Table 15. Indolent Lymphoma Treatment Market Challenges
Table 16. Indolent Lymphoma Treatment Market Restraints
Table 17. Global Indolent Lymphoma Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Indolent Lymphoma Treatment Market Share by Players (2016-2021)
Table 19. Global Top Indolent Lymphoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Indolent Lymphoma Treatment as of 2020)
Table 20. Ranking of Global Top Indolent Lymphoma Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Indolent Lymphoma Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Indolent Lymphoma Treatment Product Solution and Service
Table 24. Date of Enter into Indolent Lymphoma Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Indolent Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Indolent Lymphoma Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Indolent Lymphoma Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Indolent Lymphoma Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Indolent Lymphoma Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Indolent Lymphoma Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Indolent Lymphoma Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Indolent Lymphoma Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Indolent Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Indolent Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Indolent Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Indolent Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Indolent Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Indolent Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Indolent Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Indolent Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Indolent Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Indolent Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Indolent Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Indolent Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Indolent Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Indolent Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Indolent Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Indolent Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Indolent Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Indolent Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Indolent Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Indolent Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Indolent Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Indolent Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Indolent Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Indolent Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Indolent Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Indolent Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Altor BioScience Corporation Company Details
Table 65. Altor BioScience Corporation Business Overview
Table 66. Altor BioScience Corporation Indolent Lymphoma Treatment Product
Table 67. Altor BioScience Corporation Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 68. Altor BioScience Corporation Recent Development
Table 69. Amgen Inc. Company Details
Table 70. Amgen Inc. Business Overview
Table 71. Amgen Inc. Indolent Lymphoma Treatment Product
Table 72. Amgen Inc. Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 73. Amgen Inc. Recent Development
Table 74. Astellas Pharma Inc. Company Details
Table 75. Astellas Pharma Inc. Business Overview
Table 76. Astellas Pharma Inc. Indolent Lymphoma Treatment Product
Table 77. Astellas Pharma Inc. Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 78. Astellas Pharma Inc. Recent Development
Table 79. Bayer AG Company Details
Table 80. Bayer AG Business Overview
Table 81. Bayer AG Indolent Lymphoma Treatment Product
Table 82. Bayer AG Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 83. Bayer AG Recent Development
Table 84. Boehringer Ingelheim GmbH Company Details
Table 85. Boehringer Ingelheim GmbH Business Overview
Table 86. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Product
Table 87. Boehringer Ingelheim GmbH Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 88. Boehringer Ingelheim GmbH Recent Development
Table 89. Bristol-Myers Squibb Company Company Details
Table 90. Bristol-Myers Squibb Company Business Overview
Table 91. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Product
Table 92. Bristol-Myers Squibb Company Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 93. Bristol-Myers Squibb Company Recent Development
Table 94. Celgene Corporation Company Details
Table 95. Celgene Corporation Business Overview
Table 96. Celgene Corporation Indolent Lymphoma Treatment Product
Table 97. Celgene Corporation Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 98. Celgene Corporation Recent Development
Table 99. Eli Lilly and Company Company Details
Table 100. Eli Lilly and Company Business Overview
Table 101. Eli Lilly and Company Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 102. Eli Lilly and Company Recent Development
Table 103. F. Hoffmann-La Roche Ltd. Company Details
Table 104. F. Hoffmann-La Roche Ltd. Business Overview
Table 105. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Product
Table 106. F. Hoffmann-La Roche Ltd. Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 107. F. Hoffmann-La Roche Ltd. Recent Development
Table 108. Gilead Sciences, Inc. Company Details
Table 109. Gilead Sciences, Inc. Business Overview
Table 110. Gilead Sciences, Inc. Indolent Lymphoma Treatment Product
Table 111. Gilead Sciences, Inc. Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 112. Gilead Sciences, Inc. Recent Development
Table 113. Incyte Corporation Company Details
Table 114. Incyte Corporation Business Overview
Table 115. Incyte Corporation Indolent Lymphoma Treatment Product
Table 116. Incyte Corporation Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 117. Incyte Corporation Recent Development
Table 118. Infinity Pharmaceuticals, Inc. Company Details
Table 119. Infinity Pharmaceuticals, Inc. Business Overview
Table 120. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Product
Table 121. Infinity Pharmaceuticals, Inc. Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 122. Infinity Pharmaceuticals, Inc. Recent Development
Table 123. Juno Therapeutics Inc. Company Details
Table 124. Juno Therapeutics Inc. Business Overview
Table 125. Juno Therapeutics Inc. Indolent Lymphoma Treatment Product
Table 126. Juno Therapeutics Inc. Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 127. Juno Therapeutics Inc. Recent Development
Table 128. MedImmune, LLC Company Details
Table 129. MedImmune, LLC Business Overview
Table 130. MedImmune, LLC Indolent Lymphoma Treatment Product
Table 131. MedImmune, LLC Revenue in Indolent Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 132. MedImmune, LLC Recent Development
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Indolent Lymphoma Treatment Market Share by Type: 2020 VS 2027
Figure 2. BI-836826 Features
Figure 3. ALT-803 Features
Figure 4. BMS-986016 Features
Figure 5. CC-122 Features
Figure 6. Others Features
Figure 7. Global Indolent Lymphoma Treatment Market Share by Application: 2020 VS 2027
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Indolent Lymphoma Treatment Report Years Considered
Figure 12. Global Indolent Lymphoma Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Indolent Lymphoma Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Indolent Lymphoma Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Indolent Lymphoma Treatment Market Share by Regions (2022-2027)
Figure 16. Global Indolent Lymphoma Treatment Market Share by Players in 2020
Figure 17. Global Top Indolent Lymphoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Indolent Lymphoma Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Indolent Lymphoma Treatment Revenue in 2020
Figure 19. Global Indolent Lymphoma Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Indolent Lymphoma Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Indolent Lymphoma Treatment Market Share by Type (2016-2027)
Figure 23. North America Indolent Lymphoma Treatment Market Share by Application (2016-2027)
Figure 24. North America Indolent Lymphoma Treatment Market Share by Country (2016-2027)
Figure 25. United States Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Indolent Lymphoma Treatment Market Share by Type (2016-2027)
Figure 29. Europe Indolent Lymphoma Treatment Market Share by Application (2016-2027)
Figure 30. Europe Indolent Lymphoma Treatment Market Share by Country (2016-2027)
Figure 31. Germany Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Indolent Lymphoma Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Indolent Lymphoma Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Indolent Lymphoma Treatment Market Share by Region (2016-2027)
Figure 41. China Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Indolent Lymphoma Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Indolent Lymphoma Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Indolent Lymphoma Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Indolent Lymphoma Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Indolent Lymphoma Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Indolent Lymphoma Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Indolent Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Altor BioScience Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 61. Amgen Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 62. Astellas Pharma Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 63. Bayer AG Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 64. Boehringer Ingelheim GmbH Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 65. Bristol-Myers Squibb Company Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 66. Celgene Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 67. Eli Lilly and Company Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 68. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 69. Gilead Sciences, Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 70. Incyte Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 71. Infinity Pharmaceuticals, Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 72. Juno Therapeutics Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 73. MedImmune, LLC Revenue Growth Rate in Indolent Lymphoma Treatment Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed

---